PureTech Health’s (PRTC) Buy Rating Reaffirmed at Peel Hunt

PureTech Health (LON:PRTC)‘s stock had its “buy” rating reiterated by research analysts at Peel Hunt in a research report issued on Monday,London Stock Exchange reports. They presently have a GBX 508 price objective on the stock. Peel Hunt’s price target points to a potential upside of 309.02% from the company’s current price.

PureTech Health Price Performance

PureTech Health stock traded up GBX 3.29 during midday trading on Monday, hitting GBX 124.20. 217,160 shares of the company’s stock were exchanged, compared to its average volume of 1,138,141. PureTech Health has a 52-week low of GBX 104.71 and a 52-week high of GBX 148. The stock has a 50-day moving average price of GBX 129.60 and a two-hundred day moving average price of GBX 127.04. The company has a debt-to-equity ratio of 6.33, a quick ratio of 2.51 and a current ratio of 6.59. The company has a market cap of £302.33 million, a P/E ratio of -2.70 and a beta of 0.79.

Insider Buying and Selling

In related news, insider Sharon Barber-Lui purchased 29,868 shares of PureTech Health stock in a transaction that occurred on Tuesday, July 7th. The shares were acquired at an average cost of GBX 119 per share, for a total transaction of £35,542.92. Also, insider Michele Holcomb purchased 31,481 shares of the stock in a transaction that occurred on Wednesday, July 8th. The shares were purchased at an average price of GBX 119 per share, with a total value of £37,462.39. Insiders bought a total of 147,849 shares of company stock valued at $17,594,031 over the last three months. 13.35% of the stock is owned by corporate insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.